@entity957 of the XXXX in solid organ transplant recipients.

@entity135 @entity500 @entity5 @entity1489 @entity957 @entity229 @entity205 @entity204
BACKGROUND: The increased incidence of @entity5 after solid organ transplantation is well established in the literature, yet outcome studies in this population are rare. Excluding @entity1489 , @entity957 make up most @entity135 in transplant recipients. METHODS: At our institution, of 5300 solid organ transplant recipients, 34 have had @entity135 develop. We reviewed the records of the 23 recipients whose @entity5 was treated here. RESULTS: Only 6 of the 23 recipients were alive at the time of our chart review. Of these, three had already survived 5 years. The 10 recipients diagnosed early (stage I or II) had significantly longer survival after @entity5 diagnosis than the 13 diagnosed at an advanced stage (stage III or IV) (96.0 mo vs 9.0 mo, p <.001). In all, 14 (60.8%) of the 23 recipients died of @entity5 within 2 years after diagnosis, 12 (50.2%) within 12 months. The sum of the daily doses of immunosuppressive drugs at @entity5 diagnosis was significantly greater for recipients who died within 2 years (p =.02). Furthermore, the difference in average doses of both @entity229 (p =.001) and @entity500 (p =.028) was also significantly greater for those who died within 2 years. The average dose of @entity205 was also greater, but this difference did not reach statistical significance (p =.18). The average dose of @entity229 was significantly lower for recipients diagnosed early (p =.001). This correlation between high immunosuppressive drug doses and worse outcome has not been shown previously. CONCLUSIONS: Solid organ transplant recipients who are diagnosed with advanced @entity135 while receiving high doses of immunosuppressive drugs fare extremely poorly. High doses of immunosuppressive drugs, most notably @entity229 , correlate significantly with advanced diagnosis of @entity135 and @entity204 .
